Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Safeguarding the long-term health of hematopoietic stem cell donors: a continuous and evolving process to maintain donor safety and trust.

Literature DB >> 22272697

Safeguarding the long-term health of hematopoietic stem cell donors: a continuous and evolving process to maintain donor safety and trust.

David Stroncek, Jeffrey McCullough.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Year: 2012 PMID： 22272697 PMCID： PMC3418668 DOI： 10.1586/ehm.11.78

Source DB: PubMed Journal: Expert Rev Hematol ISSN： 1747-4094 Impact factor: 2.929

× No keyword cloud information.

20 in total

1. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor.

Authors: F Falzetti; F Aversa; O Minelli; A Tabilio
Journal: Lancet Date: 1999-02-13 Impact factor: 79.321

2. The National Marrow Donor Program with emphasis on the early years.

Authors: Jeffrey McCullough; Herbert A Perkins; John Hansen
Journal: Transfusion Date: 2006-07 Impact factor: 3.157

3. Hematopoietic growth factors--use in normal blood and stem cell donors: clinical and ethical issues.

Authors: Jeffrey McCullough; Jeffrey Kahn; John Adamson; Paolo Anderlini; Richard Benjamin; Dennis Confer; Mary Eapen; Betsy Hirsch; David Kuter; Ellen Lazarus; Derwood Pamphilon; David Stroncek; Jeremy Sugarman; Robert Wilson
Journal: Transfusion Date: 2008-06-28 Impact factor: 3.157

4. Effects of granulocyte-colony stimulating factor on chromosome aneuploidy and replication asynchrony in healthy peripheral blood stem cell donors.

Authors: Betsy Hirsch; Leann Oseth; Meghan Cain; Erin Trader; Shelley Pulkrabek; Bruce Lindgren; Xianghua Luo; Mary Clay; John Miller; Dennis Confer; Daniel Weisdorf; Jeffrey McCullough
Journal: Blood Date: 2011-06-30 Impact factor: 22.113

Review 5. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association.

Authors: Bronwen E Shaw; Dennis L Confer; William Y Hwang; Derwood H Pamphilon; Michael A Pulsipher
Journal: Haematologica Date: 2011-07 Impact factor: 9.941

6. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.

Authors: Charles L Bennett; Andrew M Evens; Leslie A Andritsos; Lakshmi Balasubramanian; Mark Mai; Matthew J Fisher; Timothy M Kuzel; Cara Angelotta; June M McKoy; Julie M Vose; Philip J Bierman; David J Kuter; Steven M Trifilio; Steven M Devine; Martin S Tallman
Journal: Br J Haematol Date: 2006-10-19 Impact factor: 6.998

Review 7. Novel agents and approaches for stem cell mobilization in normal donors and patients.

Authors: Ş M Bakanay; T Demirer
Journal: Bone Marrow Transplant Date: 2011-08-29 Impact factor: 5.483

8. Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells.

Authors: Arnon Nagler; Avital Korenstein-Ilan; Aliza Amiel; Lydia Avivi
Journal: Exp Hematol Date: 2004-01 Impact factor: 3.084

Safeguarding the long-term health of hematopoietic stem cell donors: a continuous and evolving process to maintain donor safety and trust.

1. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor.

2. The National Marrow Donor Program with emphasis on the early years.

3. Hematopoietic growth factors--use in normal blood and stem cell donors: clinical and ethical issues.

4. Effects of granulocyte-colony stimulating factor on chromosome aneuploidy and replication asynchrony in healthy peripheral blood stem cell donors.

Review 5. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association.

6. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.

Review 7. Novel agents and approaches for stem cell mobilization in normal donors and patients.

8. Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells.

9. Plerixafor for autologous CD34 cell mobilization.

10. Long-term safety of filgrastim (rhG-CSF) administration.

1. We have a specific duty to maximise the safety of related donors.

2. Cell Reversal From a Differentiated to a Stem-Like State at Cancer Initiation.